Stage 2: GFR 89-60

Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death?

Protocol Name: Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death? Sponsor: Boehringer Ingelheim Indication: CKD GFR: 20-90 DETAILS >

Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death? Read More »

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure.

Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. Sponsor: AstraZeneca Indication: CKD & HTN GFR: 30-89 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. Read More »

Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease

Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease Sponsor: Vertex Indication: APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 to ≤75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease Read More »

Safety and efficacy of BAY 3283142 in patients with chronic kidney disease

Protocol Name: Safety and efficacy of BAY 3283142 in patients with chronic kidney disease Sponsor: Bayer Indication: CKD & HTN GFR: ≥20 and ≤75 DETAILS >

Safety and efficacy of BAY 3283142 in patients with chronic kidney disease Read More »

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity

Protocol Name: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Sponsor: Eli Lilly Indication: CVD and CKD Outcomes in patients with Obesity GFR: 21-75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Read More »

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier)

Protocol Name: A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier) Sponsor: Alpine Immune Sciences / Vertex Indication: IgA Nephropathy GFR: ≥30 DETAILS >

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Study of Povetacicept in Adults with IgA Nephropathy (Rainier) Read More »

Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/​- V

Protocol Name: Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/​- V Sponsor: Novartis Indication: Lupus Nephritis GFR: ≥ 25 DETAILS >

Study of Efficacy and Safety of Iptacopan in Participants With Active Lupus Nephritis Class III-IV, +/​- V Read More »

Observational Study Protocol – Fabry Disease Registry

Protocol Name: Observational Study Protocol – Fabry Disease Registry Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Observational Study Protocol – Fabry Disease Registry Read More »

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Protocol Name: A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Sponsor: AMG 20220159 A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Indication:  Antineutrophil Cytoplasmic

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis Read More »

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B)

Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Sponsor: Dimerix B Indication: FSGS GFR: > 30 Primary Investigator: Kim Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

ACTION3: Study of Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (Dimerix B) Read More »